2,043,823 Shares in West Pharmaceutical Services, Inc. $WST Bought by Bank of New York Mellon Corp
Bank of New York Mellon Corp has acquired a new position in West Pharmaceutical Services, Inc. (NYSE:WST), purchasing over 2 million shares valued at approximately $733.7 million, representing a 2.9% stake in the company. Institutional investors now own 93.9% of the medical instruments supplier. West Pharmaceutical Services recently exceeded quarterly earnings expectations and maintains a "Moderate Buy" consensus rating from analysts.
Here's Why You Should Add INSP Stock to Your Portfolio Now
Inspire Medical Systems (INSP) is considered a strong buy due to its significant product transition and potential for growth in the underpenetrated obstructive sleep apnea (OSA) market. Despite a recent stock decline, the company is expanding its Inspire V system adoption, backed by strong clinical evidence and efforts to improve patient access. Challenges include reimbursement disruptions and potential pressure from GLP-1 therapies, but positive estimate revisions suggest a favorable outlook for 2026.
MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor
MiniMed Group, Inc. has announced the commercial shipment of its MiniMed Flex system in the United States, now featuring Abbott Laboratories' Instinct sensor. This integration combines MiniMed's app-controlled insulin pump with a sensor offering up to 15 days of wear, providing a more discreet and hands-free approach to diabetes management. The move is expected to support MiniMed's growth prospects and strengthen its competitive position in the insulin pump market.
Madison Asset Management LLC Invests $9.90 Million in West Pharmaceutical Services, Inc. $WST
Madison Asset Management LLC has acquired a new stake of 27,574 shares, valued at approximately $9.90 million, in West Pharmaceutical Services, Inc. This investment highlights continued institutional interest in the medical instruments supplier, with other hedge funds also increasing their positions. The company has recently received positive analyst ratings, an increased price target, and reported strong quarterly earnings, along with a declared quarterly dividend.
PHG|Koninklijke Philips NV|Price:27.620|Chg%:+0.520
Koninklijke Philips NV (PHG) exhibits healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Healthcare Equipment & Supplies industry. Institutional ownership is notably high, and recent analyst ratings suggest a "Buy" with a significant upside. Despite strong market performance and fundamentals, technical indicators show a sideways trading pattern, suggesting suitability for range-bound swing trading.
Generation Investment Management LLP Invests $728.17 Million in West Pharmaceutical Services, Inc. $WST
Generation Investment Management LLP has acquired a new position in West Pharmaceutical Services, Inc. (NYSE:WST), purchasing over 2 million shares valued at approximately $728.17 million. This makes West Pharmaceutical Services the 5th largest holding for the investment firm, comprising 7.1% of its portfolio. Several other institutional investors also increased their stakes in the medical instruments supplier during recent quarters.
410,699 Shares in West Pharmaceutical Services, Inc. $WST Acquired by Deutsche Bank AG
Deutsche Bank AG has acquired a new position of 410,699 shares in West Pharmaceutical Services, Inc. (NYSE:WST), valued at approximately $147.44 million. This acquisition makes Deutsche Bank AG a significant institutional holder with about 0.58% of the company's stock. The article also details other hedge fund activities, analyst ratings, and financial performance of West Pharmaceutical Services.
Great Lakes Advisors LLC Takes $5.64 Million Position in Thermo Fisher Scientific Inc. $TMO
Great Lakes Advisors LLC has acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) by purchasing 11,255 shares worth approximately $5.64 million during the second quarter. This move comes as institutional investors collectively own 89.23% of the company, and Thermo Fisher Scientific recently reported strong quarterly earnings of $6.03 per share, surpassing estimates, with revenue increasing 10.5% year-over-year. Despite a recent downgrade from HSBC, the company maintains a "Moderate Buy" consensus rating among analysts with an average price target of $619.41.
BlackRock Inc. Buys Shares of 6,651,784 West Pharmaceutical Services, Inc. $WST
BlackRock Inc. has acquired a new position of 6,651,784 shares in West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, valued at approximately $2.38 billion. This purchase makes BlackRock Inc. the owner of 9.45% of West Pharmaceutical Services' stock. Other institutional investors like State Street Corp, Artisan Partners Limited Partnership, Bank of New York Mellon Corp, Geode Capital Management LLC, and Generation Investment Management LLP have also recently adjusted their holdings in the medical instruments supplier.
West Pharmaceutical stock steadies after institutional buying as shares trade near 52-week highs
West Pharmaceutical Services (WST) stock is trading near its 52-week highs, supported by strong institutional ownership (93.90%) and a positive analyst consensus. Analysts have an average target price of $404.73, suggesting further upside from its current trading range around $346. These factors, combined with the company's critical role in pharmaceutical packaging and delivery systems, position the stock for potential movement based on its upcoming estimated earnings release on October 22, 2026.
Intuitive Surgical Expands Manufacturing Footprint in Asia Pacific
Intuitive Surgical (ISRG) is expanding its manufacturing presence in Asia Pacific with a new 316,000-square-foot facility in Penang, Malaysia. This move aims to meet the rising demand for robotic-assisted surgery in the region and strengthen the company's global manufacturing network. The facility, expected to begin operations in 2028, will create approximately 1,200 jobs and produce surgical instruments and electromechanical devices for its da Vinci surgical systems.
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos Corporation (GKOS) is identified as a stock to retain due to strong growth prospects from its iDose TR and Epioxa franchises, leading to an increased sales outlook and margin expansion. Despite potential challenges like Medicare coverage uncertainty for iDose and temporary revenue volatility for Epioxa, the company's diversified pipeline across various ophthalmic therapeutic platforms supports long-term growth. Glaukos has demonstrated strong financial performance, with significant earnings surprises and positive stock performance year-to-date.
Smith+Nephew Launches FLOW FLEXTEND COBLATION Wand for Hip Surgery
Smith+Nephew has launched the FLOW FLEXTEND COBLATION Wand, a new RF resection technology designed for hip, knee, and shoulder surgeries. This wand features an adjustable-angle tip for better joint access and precise tissue removal in complex procedures, expanding the company's COBLATION portfolio. While SNN shares initially dipped, the innovative design is expected to strengthen Smith+Nephew's position in sports medicine and arthroscopy, potentially boosting revenue in the growing arthroscopic devices market.
Pallas Capital Advisors LLC Acquires New Position in West Pharmaceutical Services, Inc. $WST
Pallas Capital Advisors LLC has acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST), purchasing 6,349 shares valued at approximately $2.28 million. This move comes as other institutional investors have also adjusted their positions in the medical instruments supplier, with several firms increasing their holdings. West Pharmaceutical Services recently reported strong quarterly earnings, beating analyst estimates, and declared a quarterly dividend.
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED Corporation (CNMD) is poised for growth due to strong adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, along with increasing robotic procedure volumes and ASC penetration. The company's organic sales growth is healthy, particularly in Orthopedic Surgery and driven by regulatory tailwinds for Buffalo Filter and the growth of BioBrace. However, challenges include moderating AirSeal growth expectations and ongoing tariff headwinds that impact earnings despite a recent refund.
West Pharmaceutical's Long-Term Growth Intact
West Pharmaceutical, a global leader in primary packaging and delivery components for injectable therapeutics, is expected to maintain its long-term growth. The company's critical components are essential for drug stability and purity, leading to strong customer trust. Its product lines support a wide range of injectable medications, including biologics and GLP-1 obesity drugs.
Microchip Technology's (MCHP) "Overweight" Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald has reiterated its "Overweight" rating for Microchip Technology (MCHP) and maintained a $125 price target, indicating a 57.89% potential upside. Despite some recent target reductions from other firms, the overall analyst sentiment remains positive with a "Moderate Buy" consensus. Microchip Technology recently surpassed quarterly earnings expectations, reporting $0.76 EPS on $1.48 billion in revenue.
West Pharmaceutical Services (WST): Analyst Consensus And 15.83% Potential Upside
West Pharmaceutical Services (WST) is a key healthcare player specializing in injectable drug delivery systems, showing strong market presence and promising growth. The company, with a market capitalization of $24.59 billion and a stock price of $349.42, has a robust forward P/E of 35.07 and revenue growth of 13.80%. Analysts are highly optimistic, with 14 buy ratings and an average target price of $404.73, suggesting a potential upside of 15.83%.
GSA Capital Partners LLP Makes New Investment in PepGen, Inc. $PEPG
GSA Capital Partners LLP has initiated a new investment in PepGen, Inc. (NASDAQ:PEPG), acquiring 852,852 shares valued at approximately $1.535 million, representing a 1.23% stake. This investment comes as institutional ownership in PepGen collectively stands at 58.01%. The company recently reported better-than-expected quarterly EPS of -$0.26, and analysts maintain a "Moderate Buy" rating with an average price target of $11.50.
Is West Pharmaceutical Services (WST) Undervalued After Its Run to $349.42?
West Pharmaceutical Services (WST) has seen significant share price appreciation and currently trades at $349.42, with analysts estimating a fair value of around $404, suggesting it is undervalued by approximately 13.5%. The company's growth is driven by GLP-1 exposure and plans for operational efficiencies, though its P/E ratio of 43.5x is higher than industry averages, indicating investors are paying a premium. Investors are encouraged to assess whether the company's growth prospects fully justify this premium.
Is West Pharmaceutical Services (WST) Undervalued After Its Run to $349.42?
West Pharmaceutical Services (WST) has seen significant share price appreciation over the past year, currently trading at $349.42. While analysts project a fair value of around $404, suggesting it might be undervalued, the company's P/E ratio is higher than industry and peer averages. The potential for growth from GLP-1 related revenues and operational efficiencies are key factors in its valuation, though risks like tariffs and demand uncertainty exist.
WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
West Pharmaceutical Services (WST) stock has seen a significant rally, surging 38.1% since the end of March, driven by strong organic revenue growth and increased adjusted EPS. The company benefits from high demand for its proprietary products, particularly those used in biologics, biosimilars, and GLP-1 therapies, alongside improvements in manufacturing productivity and compliance upgrades. Despite potential near-term execution risks and competitive pressures, WST maintains a favorable growth outlook.
West Pharmaceutical (WST) Upgraded to Buy: Here's Why
West Pharmaceutical (WST) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's underlying business and could lead to a favorable impact on its stock price. The Zacks Rank system emphasizes the strong correlation between earnings estimate revisions and near-term stock movements, indicating WST's potential for market-beating returns.
Zacks Research Has Optimistic Outlook of WST Q3 Earnings
Zacks Research has updated its Q3 2026 earnings per share (EPS) estimate for West Pharmaceutical Services (NYSE: WST) to $2.14, maintaining a "Hold" rating. This optimistic outlook follows West Pharmaceutical's recent strong quarterly performance, where the company exceeded earnings and revenue expectations and raised its 2026 outlook. Despite positive sentiment from analysts and a "Moderate Buy" average rating, the stock's high valuation (around 44 times earnings) poses a potential limitation to upside.
West Pharmaceutical Services (NYSE:WST) Rating Lowered to Hold at Zacks Research
Zacks Research downgraded West Pharmaceutical Services (NYSE:WST) from "strong buy" to "hold" despite the company reporting strong quarterly results, exceeding EPS and revenue estimates. The broader analyst consensus remains a "Moderate Buy" with an average price target of $368.08. West Pharmaceutical Services posted Q2 EPS of $2.37 on revenue of $872.3 million, a 13.8% increase year-over-year, and forecast full-year 2026 EPS between $8.85 and $9.05.
West Pharmaceutical Services Inc. stock underperforms Thursday when compared to competitors
West Pharmaceutical Services Inc. (WST) stock fell by 1.74% on Thursday, closing at $346.16, despite a generally positive trading day for the broader market, with the S&P 500 and Dow Jones Industrial Average both rising. The company's stock is now 10.32% below its 52-week high of $386.00, which it reached on July 23rd.
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
West Pharmaceutical Services (WST) is experiencing strong growth in its High-Value Product (HVP) segment, leading to wider margins and higher earnings expectations for 2026. However, the company trades at a significant premium compared to its industry and the S&P 500, raising questions about whether its valuation is justified despite attractive growth drivers. Investors face a decision between the company's improving operational case and its high valuation, especially given potential execution and cost risks.
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
West Pharmaceutical Services (WST) exceeded Q2 expectations and raised its full-year 2026 outlook, driven by strong growth in High-Value Products (HVP). The company reported increased adjusted earnings and revenues, with proprietary products showing significant momentum. While risks remain with West Vantage and the SmartDose transition, the overall earnings trajectory and margin expansion appear positive, reinforcing West's growth story.
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
West Pharmaceutical Services (WST) is experiencing strong growth in its High-Value Product (HVP) segment, improved margins, and higher earnings expectations for 2026. However, the company trades at a significant premium compared to its industry and the broader market, despite facing execution and cost risks in some segments. While WST's balance sheet is strong and supports investments and shareholder returns, investors need to weigh its attractive growth drivers against its high valuation.
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
West Pharmaceutical Services (WST) exceeded Q2 expectations, leading to an increased 2026 outlook. The company saw accelerated organic sales growth, wider margins, and a sharp increase in adjusted earnings, primarily driven by strong demand for High-Value Products (HVP). While execution risks remain with West Vantage and the SmartDose transition, the overall earnings trajectory has improved, supported by broad HVP momentum.
WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
West Pharmaceutical Services, Inc. (WST) shares have risen 17.2% in the last three months, driven by strong growth in its High-Value Product (HVP) components and improved operating margins. The company's raised 2026 revenue and earnings outlook further supports its positive trajectory, despite its premium valuation compared to industry averages. While HVP demand is robust, slower growth in Standard Products and West Vantage, along with execution risks, pose challenges for continued upside.
Stevanato Group S.p.A. (STVN) Stock Forecasts
Morningstar has initiated coverage on Stevanato Group S.p.A. (STVN) with a narrow moat rating and a fair value estimate of USD 21.10. The shares are currently considered fairly valued at their current price of 21.52. Stevanato Group provides glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries through its Biopharmaceutical and Diagnostic Solutions segment.
West Pharmaceutical Services, Inc. $WST Stock Position Reduced by Handelsbanken Fonder AB
Handelsbanken Fonder AB has reduced its stake in West Pharmaceutical Services (NYSE:WST) by 14.8% in the second quarter, selling 8,535 shares. Despite this, institutional investors collectively own 93.9% of the company, which recently reported strong quarterly earnings exceeding analyst estimates. West Pharmaceutical Services also announced a quarterly dividend of $0.22 per share and has a consensus "Buy" rating from analysts.
Insulet Corporation (PODD) Stock forecasts
Argus has lowered its target price for Insulet Corporation (PODD) to $159.00 from its previous rating. Insulet, founded in 2000, aims to simplify continuous subcutaneous insulin infusion therapy for diabetes. The stock's current price is $144.68.
Wasatch Advisors LP Acquires Shares of 24,670 West Pharmaceutical Services, Inc. $WST
Wasatch Advisors LP has acquired 24,670 shares of West Pharmaceutical Services, Inc. (NYSE:WST), valued at approximately $8.86 million, increasing institutional ownership to 93.9%. West Pharmaceutical Services reported strong quarterly earnings, surpassing analyst expectations with $2.37 EPS and $872.3 million in revenue, leading to a generally positive analyst outlook and a "Buy" consensus rating. The company also declared a quarterly dividend of $0.22 per share.
West (WST) Stock Looks Overvalued After A 47% One Year Run
West Pharmaceutical Services (WST) has seen a significant 46.9% stock price increase over the past year, leading to concerns about its current valuation. While the company's intrinsic value estimate is roughly in line with the market, several valuation checks suggest it may be overvalued, particularly when looking at its P/E ratio compared to industry averages. The article highlights that strong demand for high-value components in biologics and biosimilars is driving investor interest, but questions whether this can sustain the current premium pricing.
Chemed Corp (CHE) Stock Forecasts
Argus has lowered its target price for Chemed Corp (CHE) to $564.00, citing the company's business activities of purchasing, operating, and divesting subsidiaries to maximize shareholder value. As of the report date, Chemed Corp's current price is $540.25. The report suggests upgrading to premium research for more detailed insights.
West Pharmaceutical (WST) CFO converts RSUs, withholds shares for taxes
West Pharmaceutical Services Inc.'s CFO, Robert W. McMahon, recently converted 7,149.205 restricted stock units (RSUs) into common stock. A portion of these shares, totaling 3,109.19, were withheld at a price of $351.37 per share to cover tax liabilities or exercise costs. This transaction, which was not executed under a Rule 10b5-1 trading plan, resulted in McMahon retaining the remaining common shares.
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
BrightSpring Health Services (BTSG) is identified as a strong buy due to robust growth in Provider Services and specialty/infusion operations, successful integration of acquired assets, and a scalable home-based care platform. Despite potential headwinds from the Inflation Reduction Act and brand-to-generic conversions, the company's shares have significantly outperformed the industry and S&P 500 year-to-date. Analysts expect strong earnings and revenue growth for 2026, making it a compelling addition to an investment portfolio.
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
NeuroPace (NPCE) reported strong second-quarter 2026 results, with earnings and revenues surpassing Zacks Consensus Estimates, driven by significant growth in its RNS System. The company also raised its full-year 2026 revenue guidance and improved its adjusted EBITDA loss outlook. NeuroPace highlighted advancements in AI-based clinical decision-support tools and progress in its idiopathic generalized epilepsy program, signaling continued innovation and market expansion.
GE HealthCare Technologies Inc. (GEHC) latest stock news and headlines
This article provides a compilation of recent news and headlines regarding GE HealthCare Technologies Inc. (GEHC), detailing its stock performance, financial updates, and product innovations. It highlights GEHC's stock activity, including recent movements and performance against the S&P 500, alongside reports on strong Q2 earnings, product expansions, and analyst ratings.
Assenagon Asset Management S.A. Has $23.25 Million Position in West Pharmaceutical Services, Inc. $WST
Assenagon Asset Management S.A. significantly reduced its stake in West Pharmaceutical Services (NYSE:WST) by 52.9% in Q2, retaining 64,754 shares valued at $23.25 million. Despite this, institutional investors own 93.9% of the company, and analysts maintain a consensus "Buy" rating with an average price target of $368.08. West Pharmaceutical Services reported strong Q2 earnings, exceeding expectations with $2.37 adjusted EPS and $872.3 million in revenue, alongside declaring a $0.22 quarterly dividend.
West Pharmaceutical Services, Inc. $WST Position Reduced by Seilern Investment Management Ltd
Seilern Investment Management Ltd reduced its stake in West Pharmaceutical Services (NYSE:WST) by 38.8% in Q2 2026, selling 87,791 shares and retaining 138,230 shares worth $49.6 million. Despite this reduction, WST remains Seilern's 7th largest holding, and institutional investors collectively own 93.9% of the company. West Pharmaceutical Services reported strong Q2 earnings, exceeding analyst expectations with an EPS of $2.37 and revenue of $872.3 million, and analysts maintain a "Buy" rating with an average price target of $368.08.
ETFs Investing in West Pharmaceutical Services, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of West Pharmaceutical Services, Inc. The ETFs are sorted by market value and include details such as weight, issuer, management style, expense ratio, assets under management (AUM), price, and 3-year NAV total return. The information aims to help investors find accessible and lower-risk investment opportunities.
Bank of America Corp DE Sells 150,033 Shares of West Pharmaceutical Services, Inc. $WST
Bank of America Corp DE reduced its stake in West Pharmaceutical Services, Inc. (WST) by 28.2% in the first quarter, selling 150,033 shares but still retaining 381,813 shares valued at approximately $95.7 million. Despite this sale, institutional investors collectively own 93.9% of the company. West Pharmaceutical Services reported strong Q1 earnings, exceeding expectations with $2.37 EPS on $872.3 million revenue, and analysts maintain a "Buy" rating with a $368.08 price target.
How Q2 Results and Alina GLP-1 Approvals At Stevanato Group (STVN) Have Changed Its Investment Story
Stevanato Group (STVN) recently reported Q2 2026 results with increased sales but decreased net income, and narrowed its full-year guidance. Simultaneously, its Alina variable-dose pen injector received European marketing authorizations for liraglutide-based products, highlighting its growth in GLP-1 and self-administered injectable therapies. These developments reshape the company's investment outlook by confirming the adoption of its devices in commercially approved therapies, while also underscoring execution risks related to margins and capital investments.
Insperity, Inc. (NSP) Latest Stock News & Headlines
This article provides a compilation of recent news and headlines concerning Insperity, Inc. (NSP), covering various financial reports, analyst opinions, and market performance updates. It highlights the company's Q2 earnings, strategic initiatives like HRScale, and overall stock performance against the S&P 500. The stock has shown a significant YTD return but negative returns over one and three years compared to the benchmark.
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day
West Pharmaceutical Services Inc. (WST) shares rose 1.57% to $354.07, outperforming the broader market on a strong trading day. The S&P 500 Index and Dow Jones Industrial Average also saw gains. WST closed 8.27% below its 52-week high.
QIAGEN N.V. (NYSE: QGEN) sets $0.35 dividend and $200M buyback cap
QIAGEN N.V. (NYSE: QGEN) announced it will convene its 2026 Annual General Meeting on June 24, 2026. Shareholders will vote on a proposed cash dividend of $0.35 per ordinary share, totaling approximately $72 million, payable July 14, 2026. Additionally, the agenda includes authorizing a synthetic share repurchase of up to $200 million via capital repayment, alongside other corporate governance and remuneration policy updates.
FMR LLC reports 5.0% ownership of West Pharmaceutical (WST) common stock
FMR LLC has disclosed a 5.0% beneficial ownership stake in West Pharmaceutical (WST) common stock, totaling 3,559,015.80 shares as of June 30, 2026. The filing indicates FMR LLC holds sole dispositive power over these shares and sole voting power over a slightly smaller portion. Abigail P. Johnson also holds sole dispositive power over the same number of shares, as detailed in the Schedule 13G filing.
